Upregulated steroidogenic capacity (Magoffin, 2007) and increases in androstenedione, testosterone, and DHEA levels (Benjamin et al., 2021) may be in part compensating for the reductions in ovarian AR expression in patients with PCOS (Gao et al., 2020). The gene discussed is AR; the disease is polycystic ovary syndrome.